Tegileridine Combined With Intercostal Nerve Block After Thoracoscopic Lung Resection (NCT07386626) | Clinical Trial Compass
RecruitingNot Applicable
Tegileridine Combined With Intercostal Nerve Block After Thoracoscopic Lung Resection
China118 participantsStarted 2026-03-18
Plain-language summary
Combining tegileridine PCIA with ICNB targeting peripheral nerves, may constitute an ideal analgesic model with complementary advantages. Thus potentially achieving the analgesic goal of "early pain relief, stable throughout the process, and rapid recovery," and may have a positive impact on reducing CPSP.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age range: 18 to 75 years old;
* Patients undergoing elective thoracoscopic lobectomy or segmentectomy;
* ASA classification levels I-III;
* BMI 18 \~ 30 kg/m2。
* Voluntarily participate and sign an informed consent form.
Exclusion Criteria:
* Patients with preoperative alcohol dependence and long-term use of analgesic drugs are receiving analgesic treatment for other acute and chronic pain;
* Pregnant or lactating women;
* Allergies or other contraindications to the anesthetics, analgesics, and antiemetic drugs used in the study;
* Patients with severe sleep apnea syndrome or acute or severe bronchial asthma;
* Suffering from mental and neurological disorders or cognitive impairment, known or suspected gastrointestinal obstruction, severe liver and kidney dysfunction (Child Pugh score C), chronic obstructive pulmonary disease or severe cardiovascular disease, etc;
* Researchers consider participants who are not suitable to participate in this study and those who refuse to participate.